DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.

This study used a duck hepatitis B virus (DHBV) model to evaluate whether a novel DNA vaccination protocol alone or associated with antiviral (lamivudine) treatment was able to clear the intrahepatic covalently closed, circular viral DNA (cccDNA) pool responsible for persistence of infection. DHBV carriers received DNA vaccine (on weeks 6, 10, 13, 14, 28 and 35) targeting the large envelope and/or core proteins alone or combined with lamivudine treatment (on weeks 1-8) or lamivudine monotherapy. After 10 months of follow-up, a dramatic decrease in viraemia and liver DHBV cccDNA (below 0.08 cccDNA copies per cell) was observed in 9/30 ducks (30 %) receiving DNA mono- or combination therapy, compared with 0/12 (0 %) from lamivudine monotherapy or the control groups, suggesting a significant antiviral effect of DNA immunization. However, association with the drug did not significantly improve DHBV DNA vaccine efficacy (33 % cccDNA clearance for the combination vs 27 % for DNA monotherapy), probably due to the low antiviral potency of lamivudine in the duck model. Seroconversion to anti-preS was observed in 6/9 (67 %) ducks showing cccDNA clearance, compared with 1/28 (3.6 %) without clearance, suggesting a significant correlation (P<0.001) between humoral response restoration and cccDNA elimination. Importantly, an early (weeks 10-12) drop in viraemia was observed in seroconverted animals, and virus replication did not rebound following the cessation of immunotherapy, indicating a sustained effect. This study provides the first evidence that therapeutic DNA vaccination is able to enhance hepadnaviral cccDNA clearance, which is tightly associated with a break in humoral immune tolerance. These results also highlight the importance of antiviral drug potency and an effective DNA immunization protocol for the design of therapeutic vaccines against chronic hepatitis B.

[1]  L. Cova.  DNA vaccine: a promising new approach for chronic hepatitis B therapy. , 2007, Future virology.

[2]  B. Tennant,et al.  Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection , 2007, Hepatology.

[3]  F. Zoulim,et al.  Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. , 2006, The Journal of general virology.

[4]  S. Gujar,et al.  Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity , 2006, Journal of Virology.

[5]  Y. Sung,et al.  Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study , 2006, Gene Therapy.

[6]  C. Burrell,et al.  Covalently Closed Circular DNA Is the Predominant Form of Duck Hepatitis B Virus DNA That Persists following Transient Infection , 2005, Journal of Virology.

[7]  Mengji Lu,et al.  Immunization with the Gene Expressing Woodchuck Hepatitis Virus Nucleocapsid Protein Fused to Cytotoxic-T-Lymphocyte-Associated Antigen 4 Leads to Enhanced Specific Immune Responses in Mice and Woodchucks , 2005, Journal of Virology.

[8]  Y. Hiasa,et al.  In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  F. Zoulim.  Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance? , 2004, Antiviral chemistry & chemotherapy.

[10]  D. Scott‐Algara,et al.  Induction or expansion of T‐cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers , 2004, Hepatology.

[11]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[12]  G. Deléage,et al.  Identification of Antigenic Regions of Duck Hepatitis B Virus Core Protein with Antibodies Elicited by DNA Immunization and Chronic Infection , 2004, Journal of Virology.

[13]  F. Zoulim,et al.  Duck hepatitis B virus model in the study of hepatitis B virus. , 2004, Methods in Molecular Medicine.

[14]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[15]  P. Marion,et al.  Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection , 2003, Antimicrobial Agents and Chemotherapy.

[16]  F. Zoulim,et al.  Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model , 2003, Antimicrobial Agents and Chemotherapy.

[17]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Gibbs,et al.  Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. , 2003, Journal of hepatology.

[19]  K. Walters,et al.  Half-Life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool In Vivo following Inhibition of Viral Replication , 2002, Journal of Virology.

[20]  M. Michel,et al.  DNA Vaccines for Prophylactic or Therapeutic Immunization against Hepatitis B , 2001, Intervirology.

[21]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[22]  L. Stuyver,et al.  Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.

[23]  C. Trépo,et al.  Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein. , 2000, Vaccine.

[24]  C. Trépo,et al.  Maternally Transferred Antibodies from DNA-Immunized Avians Protect Offspring against Hepadnavirus Infection , 2000, Journal of virology.

[25]  O. Yokosuka,et al.  Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses. , 2000, Journal of hepatology.

[26]  Yung-chi Cheng,et al.  Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model , 2000, Antimicrobial Agents and Chemotherapy.

[27]  N. Restifo,et al.  DNA and RNA-based vaccines: principles, progress and prospects. , 1999, Vaccine.

[28]  David Hl.  DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. , 1999 .

[29]  C. Sunyach,et al.  Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. , 1999, Gastroenterology.

[30]  Mengji Lu,et al.  Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection , 1999, Journal of Virology.

[31]  D. Miller,et al.  Protective Efficacy of DNA Vaccines against Duck Hepatitis B Virus Infection , 1998, Journal of Virology.

[32]  W. Mason,et al.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.

[33]  R. Purcell,et al.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Schleef,et al.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Trépo,et al.  Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning. , 1994, Virology.

[36]  Tsung-Teh Wu,et al.  Characterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus , 1994, Hepatology.